Akoustis Technologies Inc. logo

Akoustis Technologies Inc. (AKTS)

Market Closed
27 Oct, 08:00 PM
NASDAQ (CM) NASDAQ (CM)
$
16. 45
+0.72
+4.5772%
After Hours
$
19. 80
+3.35 +20.3647%
845.44M Market Cap
- P/E Ratio
- Div Yield
324,709 Volume
-0.73 Eps
$ 15.73
Previous Close
Analysts:
Add Transaction
Day Range
15.59 16.69
Year Range
14.72 34.19
Want to track AKTS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

AKTS closed today higher at $16.45, an increase of 4.5772% from yesterday's close, completing a monthly decrease of -15.2499% or -$2.96. Over the past 12 months, AKTS stock lost -39.0741%.
AKTS is not paying dividends to its shareholders.
The last earnings report, released on Nov 12, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Akoustis Technologies Inc. has completed 1 stock splits, with the recent split occurring on Apr 24, 2015.
The company's stock is traded on one exchange.

AKTS Chart

People also search for

Karooooo Ltd.
$ 64.46
-0.4171%
BioLife Solutions Inc.
$ 38.61
0%
Aehr Test Systems, Inc.
$ 63.95
+12.9859%
Bitdeer Technologies Group Class A Ordinary Shares
$ 7.54
+6.422%
Anterix Inc.
$ 85.62
+7.5088%
Aktis Oncology: Padcev Is Building The Market It Wants

Aktis Oncology: Padcev Is Building The Market It Wants

Aktis Oncology is undervalued, trading below IPO price despite robust cash reserves and two independent clinical programs. AKTS has a cash runway into 2029, supported by $517.3M in cash and a $1.2B+ partnership with Eli Lilly, minimizing near-term dilution risk. AKY-1189 and AKY-2519 offer differentiated radiopharma approaches, with Fast Track status and early human dosimetry data de-risking development.

Seekingalpha | 1 week ago
Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seekingalpha | 1 month ago
Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks

Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks

A pullback in the AI trade has created opportunities for bargain-hunting investors, according to analysts at Bank of America.

Investopedia | 2 months ago

Akoustis Technologies Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Curtis Ellergodt
Curtis Ellergodt Rothschild Investment LLC
39 $1,257 $613.47 -$643.53 -51.2%
NA
Nizar Araji National Bank Of Canada /FI/
700 $22,561 $11,067 -$11,494 -50.95%
George Soros
George Soros Soros Fund Management LLC
100,000 $1.79M $1.62M -$165,850 -9.27%
John H. Burbank III
John H. Burbank III Passport Capital LLC
996,351 $17.82M $15.8M -$2.02M -11.35%
MM
Mike Muhizi SG Americas Securities LLC
3,368 $109,000 $52,978.64 -$56,021.36 -51.4%

Akoustis Technologies Inc. Analysts

Name Quantity Cost Value Profit ($) Gain (%)
JJ
Jeff Jones Oppenheimer
2,483.02 $59,741.36 $39,057.84 -$20,683.52 -34.62%

Akoustis Technologies Inc. (AKTS) FAQ

What is the stock price today?

The current price is $16.45.

On which exchange is it traded?

Akoustis Technologies Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is AKTS.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 845.44M.

Has Akoustis Technologies Inc. ever had a stock split?

Akoustis Technologies Inc. had 1 splits and the recent split was on Apr 24, 2015.

Akoustis Technologies Inc. Profile

Communications Equipment Industry
Information Technology Sector
Matthew Roden CEO
NASDAQ (CM) Exchange
01021M104 CUSIP
US Country
79 Employees
- Last Dividend
24 Apr 2015 Last Split
14 Mar 2017 IPO Date

Overview

Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., designs, develops, manufactures, and sells innovative radio frequency (RF) filter products for the global mobile wireless device industry. The company operates primarily through two business segments: Foundry Fabrication Services and RF Filters. With facilities located in the United States, Asia, and Europe, Akoustis Technologies serves a worldwide customer base. Founded in 2013, the company's headquarters is in Huntersville, North Carolina. It is dedicated to providing state-of-the-art RF solutions for mobile devices, cellular infrastructure, Wi-Fi customer premise equipment, as well as military and defense applications.

Products and Services

  • Foundry Fabrication Services
  • This segment offers specialized engineering review services and backend packaging solutions to clients. It is geared towards companies looking for custom fabrication services in the RF domain, leveraging Akoustis Technologies' expertise and facilities to meet specific design and manufacturing needs.

  • RF Filters Segment
  • Under this segment, Akoustis Technologies manufactures and sells a wide range of RF filter products. These products are essential components in various applications, including:

    • Mobile Wireless Devices: The company produces RF filters that are crucial for the performance of smartphones, tablets, and other mobile wireless devices, enabling them to connect to cellular networks efficiently.
    • Cellular Infrastructure Equipment: Akoustis' filters are also used in infrastructure equipment that forms the backbone of cellular networks, ensuring reliable communication and coverage.
    • Wi-Fi Customer Premise Equipment: In addition to cellular applications, the company's filters play a key role in enhancing the performance and reliability of Wi-Fi equipment used in homes and businesses.
    • Military and Defense Applications: Akoustis Technologies also addresses the stringent requirements of military and defense applications with its high-performance RF filters, contributing to secure and reliable communication systems.

Contact Information

Address: 17 Drydock Avenue
Phone: 617-461-4023